NOHO LABS
Live / Allowed — Published for opposition (as of 10 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 07 Jul 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99270242
- Mark type
- Stylized text
- Filed
- 07 Jul 2025
- Published for opposition
- 10 Mar 2026
- Attorney of record
- Thomas Dietrich
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for peptide therapy for the treatment and management of musculoskeletal and recovery conditions, namely muscle wasting, sarcopenia, soft tissue injuries, tendon injuries, and wound healing, dermatological conditions, namely skin aging, wrinkles, skin laxity, and hair loss, fatigue, energy, and cognitive conditions, namely chronic fatigue, low energy, age-related cognitive decline, and sleep disorders, age-related conditions, namely growth hormone deficiency, age-related muscle loss, and osteoporosis, inflammatory conditions, namely chronic inflammation and joint inflammation, sexual health disorders, namely erectile dysfunction, hypoactive sexual desire disorder, and hypogonadism, and metabolic disorders, namely obesity, overweight conditions, insulin resistance, and metabolic syndromes; Syringes sold filled with peptide preparations for the treatment and management of musculoskeletal and recovery conditions, namely muscle wasting, sarcopenia, soft tissue injuries, tendon injuries, and wound healing, dermatological conditions, namely skin aging, wrinkles, skin laxity, and hair loss, fatigue, energy, and cognitive conditions, namely chronic fatigue, low energy, age-related cognitive decline, and sleep disorders, age-related conditions, namely growth hormone deficiency, age-related muscle loss, and osteoporosis, inflammatory conditions, namely chronic inflammation and joint inflammation, sexual health disorders, namely erectile dysfunction, hypoactive sexual desire disorder, and hypogonadism, and metabolic disorders, namely obesity, overweight conditions, insulin resistance, and metabolic syndromes; Pharmaceutical preparations for skin care; Therapeutic pharmaceutical for the treatment of aging, hormone imbalance, and other health conditions via peptide therapy; Pharmaceutical preparations for the treatment of aging-related conditions, hormone imbalances, and other health conditions via peptide therapy; Pharmaceutical preparations for the treatment and prevention of aging-related conditions; Diagnostic preparations for medical or veterinary purposes in the nature of peptide substrates; Synthetic peptides for the treatment and management of musculoskeletal and recovery conditions, namely muscle wasting, sarcopenia, soft tissue injuries, tendon injuries, and wound healing, dermatological conditions, namely skin aging, wrinkles, skin laxity, and hair loss, fatigue, energy, and cognitive conditions, namely chronic fatigue, low energy, age-related cognitive decline, and sleep disorders, age-related conditions, namely growth hormone deficiency, age-related muscle loss, and osteoporosis, inflammatory conditions, namely chronic inflammation and joint inflammation, sexual health disorders, namely erectile dysfunction, hypoactive sexual desire disorder, and hypogonadism, and metabolic disorders, namely obesity, overweight conditions, insulin resistance, and metabolic syndromes
- Class 044 — Medical, beauty and agricultural services: Telemedicine services; Health care services for treating aging and loss of biological function through peptide therapy; Providing personalized healthcare and medical information in the nature of peptide therapy; Health care services, namely, peptide therapy; Health care consulting in the field of peptide therapy; Providing healthy lifestyle and nutrition services, namely, personal assessments, personalized routines, maintenance schedules, and counseling
Owner
- Eterna Technologies Corporation, San Francisco, CA, US
- Eterna Technologies Corporation, San Francisco, CA, US
Prosecution history
- 10 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 10 Mar 2026 — PUBLISHED FOR OPPOSITION
- 04 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Jan 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 22 Jan 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 22 Jan 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 07 Jan 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 07 Jan 2026 — NON-FINAL ACTION E-MAILED
- 07 Jan 2026 — NON-FINAL ACTION WRITTEN
- 12 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 12 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 12 Dec 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 25 Nov 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 25 Nov 2025 — NON-FINAL ACTION E-MAILED